Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

88.11USD
24 Mar 2017
Change (% chg)

$0.30 (+0.34%)
Prev Close
$87.81
Open
$87.97
Day's High
$88.94
Day's Low
$87.76
Volume
48,842
Avg. Vol
113,008
52-wk High
$91.57
52-wk Low
$67.21

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories and Chiesi Farmaceutici announce extension of integrated respiratory drug discovery program
Monday, 13 Mar 2017 08:00am EDT 

Charles River Laboratories International Inc - : Charles River Laboratories and Chiesi Farmaceutici Spa announce extension of integrated respiratory drug discovery program .To provide Chiesi portfolio of drug discovery capabilities to help test Chiesi's candidates for preclinical development.  Full Article

Charles River Labs says acquires Agilux Labs for $64 mln
Wednesday, 28 Sep 2016 04:30pm EDT 

Charles River Laboratories International Inc : Charles river laboratories acquires Agilux Laboratories, Inc . Deal for $64 million . Says acquisition is expected to be neutral to Charles River's non-gaap earnings per share in q4 of 2016 . Agilux will be reported as part of charles river's discovery and safety assessment (dsa) segment . Purchase price was approximately $64 million in cash, . Agilux is expected to generate full-year revenue of $27 million in 2016 .Acquisition is expected to be slightly accretive to non-gaap earnings per share in 2017.  Full Article

Charles River Labs Q2 earnings per share $0.73
Wednesday, 3 Aug 2016 07:00am EDT 

Charles River Laboratories International Inc : Quarter 2016 results from continuing operations . Q2 gaap earnings per share $0.73 from continuing operations . Q2 earnings per share view $1.10 -- Thomson Reuters I/B/E/S . Q2 non-gaap earnings per share $1.20 . Q2 revenue $434.1 million versus i/b/e/s view $425.1 million . Q2 gaap earnings per share $0.73 . Sees 2016 gaap eps of $3.15-$3.25 . 2016 non-gaap eps estimate of $4.40 - $4.50 . 2016 revenue guidance range has been raised by 1% . Sees 2016 revenue growth on reported basis of 20% - 23.5% .Fy2016 earnings per share view $4.39, revenue view $1.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories International Inc reaffirms FY 2016 revenue guidance; increases FY 2016 EPS guidance
Wednesday, 4 May 2016 07:00am EDT 

Charles River Laboratories International Inc:Reaffirming its revenue growth guidance for FY 2016, including contribution from WIL Research.Increases its non-GAAP earnings per share guidance for 2016 to primarily reflect first-quarter performance, better-than-expected operating margin improvement in the RMS segment, and the inclusion of WIL Research from April 4, 2016.Increases guidance for FY 2016 non-GAAP earnings per share to a range of $4.32 to $4.45.  Full Article

Charles River Laboratories International Inc and BioMotiv enter into strategic partnership
Wednesday, 13 Apr 2016 04:30pm EDT 

Charles River Laboratories International Inc:Has entered into a strategic partnership with BioMotiv LLC.Charles River has committed to invest up to $10 million in BioMotiv.Says through agreement, Charles River will be preferred drug discovery and preclinical development partner for BioMotiv's portfolio of technologies and companies.  Full Article

Charles River Laboratories International, Inc to acquire WIL research
Thursday, 7 Jan 2016 06:30am EST 

Charles River Laboratories International, Inc:To acquire wil research.Says transaction expected to be accretive to non-GAAP EPS by at least $0.20 in 2016 and $0.45-$0.50 in 2017.Deal for about $585 million.Says the acquisition is expected to add $150 to $170 million to Charles river's 2016 consolidated revenue.Says deal to add $240 to $250 million to co's 2017 consolidated revenue.  Full Article

Charles River Laboratories International, Inc acquires Oncotest GmbH
Wednesday, 18 Nov 2015 04:15pm EST 

Charles River Laboratories International, Inc:Acquires oncotest gmbh.Deal for about EUR 34 million.Says transaction includes a potential additional payment of EUR2 million based on future performance.Deal will have a negligible impact on Charles river's consolidated revenue and non-GAAP earnings per share in Q4 2015.Says in 2016, oncotest is expected to represent approximately 1% of Charles river's consolidated revenue.Oncotest has become part of co's in vivo discovery business, which is reported in discovery and safety assessment segment.Says deal to be neutral to slightly accretive to non-GAAP earnings per share.Deal for about $36 million.  Full Article

Charles River Laboratories International Inc raises FY 2016
Wednesday, 4 Nov 2015 07:00am EST 

Charles River Laboratories International Inc:Now expect FY 2016 revenue growth in a range from 9.5% to 10% in constant currency, and non-GAAP earnings per share in a range from $3.69 to $3.74.Reported revenue of $1.298 bln in FY 2014.FY 2015 revenue of $1.346 bln and EPS of $3.64 - Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories wellcome trust-funded projects expand partnerships
Wednesday, 7 Oct 2015 08:30am EDT 

Charles River Laboratories:Says wellcome trust-funded projects expand partnerships with Charles river's global discovery services business.  Full Article

Charles River Laboratories raises FY 2015 guidance
Thursday, 30 Jul 2015 07:00am EDT 

Charles River Laboratories:Says as a result of the acquisition of Celsis, which closed on July 24, the company is increasing constant currency revenue guidance for FY 2015 to a range of 8.0%-9.5%.Expects FY 2015 non-GAAP earnings per share guidance to a range of $3.60 to $3.70.Reported revenue of $1.298 bln in FY 2014.FY 2015 revenue of $1.340 bln and EPS of $3.64 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web